The bond of Pentracor GmbH is a fixed-income security (owner bond with possible conversion right) and can be purchased at a nominal value of 1,000 euros each in the context of a private placement with a minimum subscription sum of 100,000 euros. It is expected that from 29 May 2019, the bond will be included in trading on the open market (open market) of the Frankfurt Stock Exchange and will be tradable there.
The 8.5% coupon is valid for the entire five-year term and is paid annually on 29 May of each year (first time 2021). At the end of the term, the bond will be added at 120.00 % plus interest accrued to the creditors.
The issue volume of the bond amounts to up to EUR 15 million.
The funds raised will be used specifically to implement the growth strategy with large-scale product roll-out, in particular for expanding production, expanding sales, further clinical trials and FDA approval for U.S. market entry.
The bond is subject to interest at an interest rate of 8.5% per year. The interest is paid annually retrospectively, for the first time on 29 May 2021
The term of the bond is five years, starting on 29 May 2020. The repayment will be made on 29 May 2025, the date of due date.
The bond is expected to be included in trading on the Open Market (open market) of the Frankfurt Stock Exchange from 29 May 2020 and will be tradable there.
The terms of the bond include, inter alia, the following rules on the rights of bondholders:
Details can be found in the bond terms (see financial publicationssection )
For more information, see the bond terms and the bond factsheet (see financial publicationssection).
We are also at your disposal for questions in person.
Die Ergebnisse der ersten klinischen Studie zu CRP-Apherese nach Akutem Myokardinfarkt (CAMI1) wurden im kardiologischen Fachjournal Frontiers in Cardiovascular Medicine veröffentlicht.
Falls Sie die News später lesen möchten, können Sie dies unter Aktuelles/Fachpublikationen tun.